Scholarlink

<p>The treatment of chronic lymphocytic leukemia has made immense progress in recent years. Nevertheless, different risk constellations persist even with the use of targeted therapies. One of these, unmutated IGHV status, continues to have a&#xa0;prognostic influence. This review discusses the current therapy recommendations and highlights the use of limited therapies and long-term therapies with a&#xa0;particular focus on patients harboring this risk factor.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Mind the gap in clinical practice guidelines—how I treat CLL patients with unmutated IGHV status

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年4月24日

查看全文
  • Katharina Prochazka

摘要

The treatment of chronic lymphocytic leukemia has made immense progress in recent years. Nevertheless, different risk constellations persist even with the use of targeted therapies. One of these, unmutated IGHV status, continues to have a prognostic influence. This review discusses the current therapy recommendations and highlights the use of limited therapies and long-term therapies with a particular focus on patients harboring this risk factor.